S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. – Cost Effective Supplements

S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial.

Quick navigation

Link
Conclusion
Supplements
Functions
Systems

Link to full study

http://www.ncbi.nlm.nih.gov/pubmed/11104210

Conclusion of this study

One patient experienced mild nausea, and another two patients developed mild diarrhea, which resolved spontaneously. The mean HDS score before treatment was 27.09 +/- 6.04 (mean +/- standard deviation) and was 9.55 +/- 7.29 after SAM treatment (p < 0.0001). Although uncontrolled and preliminary, this study suggests that SAM is well tolerated and may be a safe and effective alternative to the antidepressant agents currently used in patients with Parkinson's disease.